Abstract:Importance: Most studies of autosomal dominant polycystic kidney disease (ADPKD) genetics have used kidney specialty cohorts, focusing on PKD1 and PKD2. These can lead to biased estimates of population prevalence of ADPKD-associated gene variants and their phenotypic expression. Objective: To determine the prevalence of ADPKD and contributions of PKD1, PKD2, and other genes related to cystic kidney disease in a large, unselected cohort. Design, setting, and participants: This retrospective observational study used an unselected health system-based cohort in central and northeast Pennsylvania with exome sequencing (enrolled from 2004 to 2020) and electronic health record data (up to October 2021). The genotype-first approach included the entire cohort and the phenotype-first approach focused on patients with ADPKD diagnosis codes, confirmed by chart and imaging review. Exposures: Loss-of-function (LOF) variants in PKD1, PKD2, and other genes associated with cystic kidney disease (ie, ALG8, ALG9, DNAJB11, GANAB, HNF1B, IFT140, SEC61B, PKHD1, PRKCSH, SEC63); likely pathogenic missense variants in PKD1 and PKD2. Main outcomes and measures: Genotype-first analysis: ADPKD diagnosis code (Q61.2, Q61.3, 753.13, 753.12); phenotype-first analysis: presence of a rare variant in PKD1, PKD2, or other genes associated with cystic kidney disease. Results: Of 174 172 patients (median age, 60 years; 60.6% female; 93% of European ancestry), 303 patients had ADPKD diagnosis codes, including 235 with sufficient chart review data for confirmation. In addition to PKD1 and PKD2, LOF variants in IFT140, GANAB, and HNF1B were associated with ADPKD diagnosis after correction for multiple comparisons. Among patients with LOF variants in PKD1, 66 of 68 (97%) had ADPKD; 43 of 43 patients (100%) with LOF variants in PKD2 had ADPKD. In contrast, only 24 of 77 patients (31.2%) with a PKD1 missense variant previously classified as "likely pathogenic" had ADPKD, suggesting misclassification or variable penetrance. Among patients with ADPKD diagnosis confirmed by chart review, 180 of 235 (76.6%) had a potential genetic cause, with the majority being rare variants in PKD1 (127 patients) or PKD2 (34 patients); 19 of 235 (8.1%) had variants in other genes associated with cystic kidney disease. Of these 235 patients with confirmed ADPKD, 150 (63.8%) had a family history of ADPKD. The yield for a genetic determinant of ADPKD was higher for those with a family history of ADPKD compared with those without family history (91.3% [137/150] vs 50.6% [43/85]; difference, 40.7% [95% CI, 29.2%-52.3%]; P < .001). Previously unreported PKD1, PKD2, and GANAB variants were identified with pedigree data suggesting pathogenicity, and several PKD1 missense variants previously reported as likely pathogenic appeared to be benign. Conclusions and relevance: This study demonstrates substantial genetic and phenotypic variability in ADPKD among patients within a regional health system in the US.

Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy

Common variants in Mendelian kidney disease genes and their association with renal function

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

Novel Pathogenic Mutation of P209L in TRPC6 Gene Causes Adult Focal Segmental Glomerulosclerosis

TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations

[A Child with Diffuse Mesangial Sclerosis Caused by a Missense Mutation of TRPC6 Gene].

A novel gain-of-function mutation in transient receptor potential C6 that causes podocytes injury

A Functional Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated with Idiopathic Pulmonary Arterial Hypertension.

Kidney Organoids Generated Using an Allelic Series of NPHS2 Point Variants Reveal Distinct Intracellular Podocin Mistrafficking

Identification and properties of TRPV4 mutant channels present in polycystic kidney disease patients

Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants

is a novel causative gene implicated in X-linked polycystic kidney disease

Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease

A Whole Exome Sequencing Study of a small Indian Autosomal Dominant Polycystic Kidney Disease Patient Cohort

Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy

Expression of TRPC 6 in renal tissue and its significance in children with primary nephrotic syndrome

Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis

Further delineation of the clinical spectrum of KAT6B disorders and allelic series of pathogenic variants

Mutations in Six Nephrosis Genes Delineate a Pathogenic Pathway Amenable to Treatment.

CFAP47 is a novel causative gene implicated in X-linked polycystic kidney disease.

Mtor-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy